Phase 2 N=28 Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
Metastatic Castration-resistant Prostate Cancer
Primary: Progression-free Survival (PFS) — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Baclofen Effects in Cigarette Smokers
Nicotine Dependence
Primary: Cigarettes Smoked Per Day — 14.19; 14.23; 7.67; 7.76 Cigarettes per day
Phase 2 N=72 Phase II Trial for Large ER-Negative Breast Cancers
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Phase 2 N=14 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Phase 2 N=101 Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Time to Progression-Blinded Independent Central Review (BICR) Assessment — 5.6; 4.1 Months — p=0.7382
Phase 2 N=81 Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Carcinoma
Primary: Overall Response Rate — 1; 0; 2; 3 Participants — p=0.99
Phase 2 N=34 Month 30 & 42 Extension Studies of CRD-004 Primary Study
Herpes Zoster
Primary: Frequencies of Glycoprotein E (gE)-Specific Cluster of Differentiation 4 (CD4) / CD8 T Cells With at Least Two Antigen-specific Cytokines: Interferon Gamma (IFN-γ)…
Phase 2 N=114 CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
Geographic Atrophy
Primary: Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug — 0; 0; 0 subjects
Phase 2 N=25 Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematopoietic Engraftment — 17.9 days
Phase 2 N=104 An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: The Percentage of Participant With Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Within 2 Days After Any Dose in…
Phase 2 N=245 A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ — 5.42 months
Phase 2 N=44 A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in 24-hour Average Hand Pain Intensity, Averaged Over the 7 Days Prior to Week 6 — -1.34; -1.70 Scores on scale — p=0.442
Phase 2 N=12 Study of EB-001 in Facial Scar Reduction
Mohs Surgery
Primary: Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) — 0; 50 Percentage reporting improvement
Phase 2 N=117 A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in Forced Vital Capacity (FVC) [% Predicted] — -2.5; -4.8 Percentage of predicted FVC — p=0.0014
Phase 2 N=419 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density · Postmenopausal Osteoporosis
Primary: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine — -0.1; 4.1; 7.1; 5.4 percent change — p=< 0.0001